Comparison Chart Summit Therapeutics Inc.

Stocks

SMMT

US86627T1088

Biotechnology & Medical Research

Market Closed - Nasdaq 23:00:00 02/10/2026 +03			5-day change	1st Jan Change
16.76 ^USD	+0.39%		+7.34%	-4.20%

09-22	Akeso, Inc. and Summit Therapeutics Inc. Showcase HARMONi-G11 Phase III Trial Data Featuring Ivonescimab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer At ESMO 2026	CI
09-15	Summit Therapeutics Presents Updated HarmonI Data At WCLC 2026 Demonstrating Consistent Overall Survival Results With Ivonescimab Plus Chemotherapy In Western And Asian Patients	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Compared values

		Sector	Change	5-day change	YTD change	1-year change	5-year change	Capi.	ST	MT	LT
	SUMMIT THERAPEUTICS INC.	Bio Therapeutic Drugs	+0.39%	+7.34%	-4.20%	-21.82%	+227.89%	13.37B